Clinical Trial Update: Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effect of postbiotics on microbiota and systemic immunomodulation of pembrolizumab as first-line therapy in recurrent/metastatic he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Head & Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING